Medicare Part D utilization management for negotiated drugs and within-class comparators, 2019-2026

Clicks: 9
ID: 332862
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #146 of 168 articles by views in Health Affairs Scholar

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 168 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction The Inflation Reduction Act requires Medicare drug plans to cover medications selected for federal price negotiation once negotiated prices take effect, and by 2026 all ten first-round drugs were covered by every plan. Plans retain the ability to require prior authorization, step therapy, and/or quantity limits as formulary management tools. Methods Using national Medicare Part D formulary files, 2019-2026, we compared restrictions on nine of the ten negotiated medications with those on similar drugs in the same classes not selected for negotiation. Estimates were weighted by plan enrollment. Results Weighted by enrollment, step therapy on negotiated diabetes medications fell to zero by 2025 and rose to 5.0 percent in 2026, while comparators stayed below 1 percent; negotiated anticoagulants rose to 4.8 percent. Cost sharing is set by formulary tier rather than by drug and did not change. Prior authorization was near-absent in the cardiometabolic classes and near-universal in the specialty classes, with no change associated with negotiation. Conclusion Guaranteed coverage does not guarantee access. In the first year of negotiated prices, universal listing coexisted with a return of step therapy on negotiated cardiometabolic drugs that comparators did not mirror, while what beneficiaries paid at the pharmacy was unchanged.
Reference Key
openalex_W7222922009 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Vidur Jain, Rozalina G. McCoy
Are you one of these authors? Claim your profile
Journal Health Affairs Scholar
Year 2026
DOI
10.1093/haschl/qxag290
URL
https://doi.org/10.1093/haschl/qxag290
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.